Do analysts rate CSBR or QSI?

Quantum-Si has a consensus price target of $1.00, indicating a potential upside of 19.86%. Given Quantum-Si's stronger consensus rating and higher probable upside, analysts clearly believe Quantum-Si is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum-Si 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to CSBR or QSI?

In the previous week, Quantum-Si had 6 more articles in the media than Champions Oncology. MarketBeat recorded 8 mentions for Quantum-Si and 2 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 0.94 beat Quantum-Si's score of 0.16 indicating that Champions Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Champions Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum-Si 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CSBR or CDXS?

Codexis has a consensus price target of $6.50, suggesting a potential upside of 392.42%. Given Codexis' stronger consensus rating and higher probable upside, analysts clearly believe Codexis is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Codexis 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer CSBR or QTRX?

Quanterix has a consensus target price of $3.00, indicating a potential downside of 8.26%. Given Quanterix's stronger consensus rating and higher possible upside, analysts plainly believe Quanterix is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quanterix 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media refer more to CSBR or QTRX?

In the previous week, Quanterix had 4 more articles in the media than Champions Oncology. MarketBeat recorded 6 mentions for Quanterix and 2 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 0.94 beat Quanterix's score of 0.46 indicating that Champions Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Champions Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quanterix 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CSBR or MXCT?

MaxCyte has a consensus price target of $5.00, suggesting a potential upside of 327.35%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts clearly believe MaxCyte is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MaxCyte 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to CSBR or MXCT?

In the previous week, MaxCyte had 1 more articles in the media than Champions Oncology. MarketBeat recorded 3 mentions for MaxCyte and 2 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 0.94 beat MaxCyte's score of 0.71 indicating that Champions Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Champions Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NAUT or CSBR?

Nautilus Biotechnology presently has a consensus price target of $4.00, indicating a potential upside of 315.50%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Nautilus Biotechnology is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nautilus Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Champions Oncology (CSBR) Competitors

$4.90 -0.05 (-1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$4.90 0.00 (-0.08%)

As of 07:30 PM Eastern

Compare

CSBR vs. QSI, CDXS, QTRX, MXCT, and NAUT

Should you buy Champions Oncology stock or one of its competitors? Champions Oncology's main competitors and comparable companies include Quantum-Si (QSI), Codexis (CDXS), Quanterix (QTRX), MaxCyte (MXCT), and Nautilus Biotechnology (NAUT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Champions Oncology compare to Quantum-Si?

Champions Oncology (NASDAQ:CSBR) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 46.3% of Champions Oncology shares are held by company insiders. Comparatively, 22.0% of Quantum-Si shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Champions Oncology has a net margin of -1.82% compared to Quantum-Si's net margin of -6,138.26%. Champions Oncology's return on equity of -25.77% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.82%	-25.77%	-3.71%
Quantum-Si	-6,138.26%	-47.12%	-43.18%

Champions Oncology has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.25, meaning that its share price is 225% more volatile than the broader market.

Quantum-Si has a consensus price target of $1.00, indicating a potential upside of 19.86%. Given Quantum-Si's stronger consensus rating and higher probable upside, analysts clearly believe Quantum-Si is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Champions Oncology has higher revenue and earnings than Quantum-Si. Champions Oncology is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$59.42M	1.15	-$1.17M	-$0.08	N/A
Quantum-Si	$2.44M	74.84	-$101.34M	-$0.46	N/A

In the previous week, Quantum-Si had 6 more articles in the media than Champions Oncology. MarketBeat recorded 8 mentions for Quantum-Si and 2 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 0.94 beat Quantum-Si's score of 0.16 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Champions Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum-Si	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Champions Oncology beats Quantum-Si on 9 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Codexis?

Champions Oncology (NASDAQ:CSBR) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Champions Oncology has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Codexis has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

Champions Oncology has a net margin of -1.82% compared to Codexis' net margin of -39.55%. Champions Oncology's return on equity of -25.77% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.82%	-25.77%	-3.71%
Codexis	-39.55%	-74.36%	-23.58%

Champions Oncology has higher earnings, but lower revenue than Codexis. Champions Oncology is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$59.42M	1.15	-$1.17M	-$0.08	N/A
Codexis	$70.39M	2.05	-$43.97M	-$0.34	N/A

Codexis has a consensus price target of $6.50, suggesting a potential upside of 392.42%. Given Codexis' stronger consensus rating and higher probable upside, analysts clearly believe Codexis is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 46.3% of Champions Oncology shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Champions Oncology had 1 more articles in the media than Codexis. MarketBeat recorded 2 mentions for Champions Oncology and 1 mentions for Codexis. Codexis' average media sentiment score of 1.77 beat Champions Oncology's score of 0.94 indicating that Codexis is being referred to more favorably in the news media.

Company	Overall Sentiment
Champions Oncology	Positive
Codexis	Very Positive

Summary

Codexis beats Champions Oncology on 9 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Quanterix?

Champions Oncology (NASDAQ:CSBR) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Champions Oncology has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Quanterix has a consensus target price of $3.00, indicating a potential downside of 8.26%. Given Quanterix's stronger consensus rating and higher possible upside, analysts plainly believe Quanterix is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Champions Oncology has a net margin of -1.82% compared to Quanterix's net margin of -80.25%. Champions Oncology's return on equity of -25.77% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.82%	-25.77%	-3.71%
Quanterix	-80.25%	-26.09%	-19.03%

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 46.3% of Champions Oncology shares are owned by insiders. Comparatively, 1.5% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Quanterix had 4 more articles in the media than Champions Oncology. MarketBeat recorded 6 mentions for Quanterix and 2 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 0.94 beat Quanterix's score of 0.46 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Champions Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quanterix	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Champions Oncology has higher earnings, but lower revenue than Quanterix. Champions Oncology is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$59.42M	1.15	-$1.17M	-$0.08	N/A
Quanterix	$138.90M	1.11	-$107.15M	-$2.63	N/A

Summary

Champions Oncology beats Quanterix on 8 of the 15 factors compared between the two stocks.

How does Champions Oncology compare to MaxCyte?

Champions Oncology (NASDAQ:CSBR) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Champions Oncology has a net margin of -1.82% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.82%	-25.77%	-3.71%
MaxCyte	-114.77%	-18.92%	-16.14%

In the previous week, MaxCyte had 1 more articles in the media than Champions Oncology. MarketBeat recorded 3 mentions for MaxCyte and 2 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 0.94 beat MaxCyte's score of 0.71 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Champions Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Champions Oncology has higher revenue and earnings than MaxCyte. Champions Oncology is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$59.42M	1.15	-$1.17M	-$0.08	N/A
MaxCyte	$33.03M	3.66	-$44.63M	-$0.33	N/A

Champions Oncology has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 46.3% of Champions Oncology shares are held by company insiders. Comparatively, 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MaxCyte has a consensus price target of $5.00, suggesting a potential upside of 327.35%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts clearly believe MaxCyte is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

MaxCyte beats Champions Oncology on 9 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Nautilus Biotechnology?

Nautilus Biotechnology (NASDAQ:NAUT) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Nautilus Biotechnology presently has a consensus price target of $4.00, indicating a potential upside of 315.50%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Nautilus Biotechnology is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nautilus Biotechnology has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

Champions Oncology has higher revenue and earnings than Nautilus Biotechnology. Champions Oncology is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Champions Oncology	$59.42M	1.15	-$1.17M	-$0.08	N/A

Nautilus Biotechnology has a net margin of 0.00% compared to Champions Oncology's net margin of -1.82%. Champions Oncology's return on equity of -25.77% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Champions Oncology	-1.82%	-25.77%	-3.71%

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by insiders. Comparatively, 46.3% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Champions Oncology had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 2 mentions for Champions Oncology and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.82 beat Champions Oncology's score of 0.94 indicating that Nautilus Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Nautilus Biotechnology	Very Positive
Champions Oncology	Positive

Summary

Nautilus Biotechnology beats Champions Oncology on 8 of the 15 factors compared between the two stocks.

Get Champions Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSBR vs. The Competition

Export

Metric	Champions Oncology	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$68.90M	$10.94B	$7.29B	$13.10B
Dividend Yield	N/A	1.45%	2.52%	13.51%
P/E Ratio	-61.25	59.42	213.99	21.16
Price / Sales	1.15	108.00	618.37	86.16
Price / Cash	340.30	27.70	79.23	52.93
Price / Book	15.31	6.07	10.43	6.30
Net Income	-$1.17M	$56.67B	$3.49B	$359.77M
7 Day Performance	-7.55%	2.63%	-1.25%	-0.17%
1 Month Performance	-1.51%	2.99%	-4.51%	-4.06%
1 Year Performance	-23.91%	40.93%	16.42%	6.09%

Champions Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CSBR Champions Oncology	0.6477 of 5 stars	$4.90 -1.0%	N/A	-25.2%	$68.90M	$59.42M	N/A	214	Positive News Gap Down
QSI Quantum-Si	2.5867 of 5 stars	$0.73 +1.4%	$1.00 +37.0%	-51.2%	$157.60M	$2.44M	N/A	145	Analyst Upgrade
CDXS Codexis	2.6644 of 5 stars	$1.34 -4.3%	$6.50 +385.1%	-44.8%	$153.31M	$70.39M	N/A	146	News Coverage Positive News
QTRX Quanterix	0.599 of 5 stars	$2.91 +7.0%	$3.00 +3.1%	-40.0%	$128.64M	$138.90M	N/A	450	News Coverage
MXCT MaxCyte	3.4703 of 5 stars	$1.18 -0.8%	$5.00 +323.7%	-28.3%	$122.82M	$33.03M	N/A	91	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSBR) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Champions Oncology (CSBR) Competitors

CSBR vs. QSI, CDXS, QTRX, MXCT, and NAUT

How does Champions Oncology compare to Quantum-Si?

Summary

How does Champions Oncology compare to Codexis?

Summary

How does Champions Oncology compare to Quanterix?

Summary

How does Champions Oncology compare to MaxCyte?

Summary

How does Champions Oncology compare to Nautilus Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSBR vs. The Competition

Champions Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Champions Oncology (CSBR) Competitors

CSBR vs. QSI, CDXS, QTRX, MXCT, and NAUT

How does Champions Oncology compare to Quantum-Si?

Do insiders and institutionals hold more shares of CSBR or QSI?

Is CSBR or QSI more profitable?

Which has more risk and volatility, CSBR or QSI?

Do analysts rate CSBR or QSI?

Which has higher valuation and earnings, CSBR or QSI?

Does the media refer more to CSBR or QSI?

Summary

How does Champions Oncology compare to Codexis?

Which has more risk & volatility, CSBR or CDXS?

Is CSBR or CDXS more profitable?

Which has stronger valuation and earnings, CSBR or CDXS?

Do analysts rate CSBR or CDXS?

Do insiders & institutionals have more ownership in CSBR or CDXS?

Does the media refer more to CSBR or CDXS?

Summary

How does Champions Oncology compare to Quanterix?

Which has more risk & volatility, CSBR or QTRX?

Do analysts prefer CSBR or QTRX?

Is CSBR or QTRX more profitable?

Do insiders and institutionals have more ownership in CSBR or QTRX?

Does the media refer more to CSBR or QTRX?

Which has stronger earnings and valuation, CSBR or QTRX?

Summary

How does Champions Oncology compare to MaxCyte?

Is CSBR or MXCT more profitable?

Does the media refer more to CSBR or MXCT?

Which has preferable valuation and earnings, CSBR or MXCT?

Which has more volatility and risk, CSBR or MXCT?

Do insiders and institutionals hold more shares of CSBR or MXCT?

Do analysts prefer CSBR or MXCT?

Summary

How does Champions Oncology compare to Nautilus Biotechnology?

Do analysts rate NAUT or CSBR?

Which has more risk and volatility, NAUT or CSBR?

Which has preferable earnings and valuation, NAUT or CSBR?

Is NAUT or CSBR more profitable?

Do insiders & institutionals believe in NAUT or CSBR?

Does the media favor NAUT or CSBR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSBR vs. The Competition

Champions Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools